Cell Transplantation-based Regenerative Medicine in Liver Diseases
Overview
Authors
Affiliations
This review aims to evaluate the current preclinical state of liver bioengineering, the clinical context for liver cell therapies, the cell sources, the delivery routes, and the results of clinical trials for end-stage liver disease. Different clinical settings, such as inborn errors of metabolism, acute liver failure, chronic liver disease, liver cirrhosis, and acute-on-chronic liver failure, as well as multiple cellular sources were analyzed; namely, hepatocytes, hepatic progenitor cells, biliary tree stem/progenitor cells, mesenchymal stromal cells, and macrophages. The highly heterogeneous clinical scenario of liver disease and the availability of multiple cellular sources endowed with different biological properties make this a multidisciplinary translational research challenge. Data on each individual liver disease and more accurate endpoints are urgently needed, together with a characterization of the regenerative pathways leading to potential therapeutic benefit. Here, we critically review these topics and identify related research needs and perspectives in preclinical and clinical settings.
Co-existing regeneration mechanisms in severe alcohol-related steatohepatitis.
Lejeune A, Starkel P, Louvet A, Hittelet A, Bazille C, Bastens B Transl Gastroenterol Hepatol. 2025; 10:3.
PMID: 39944578 PMC: 11811559. DOI: 10.21037/tgh-24-92.
Lim R, Hodge A, Warner S, Moore G, Correia J, Krause M Stem Cells Transl Med. 2024; 13(6):522-531.
PMID: 38619045 PMC: 11165158. DOI: 10.1093/stcltm/szae023.
Slautin V, Konyshev K, Gavrilov I, Beresneva O, Maklakova I, Grebnev D Curr Stem Cell Res Ther. 2024; 19(11):1484-1496.
PMID: 38204245 DOI: 10.2174/011574888X279940231206100902.